Essex Investment Management’s Travere Therapeutics TVTX Stock Holding History

Essex Investment Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.8M	Buy	161,705 +2,996	+2%	+$89.6K	0.76%	39
2025 Q4	$6.06M	Sell	158,709 -3,279	-2%	-$107K	0.92%	31
2025 Q3	$3.87M	Buy	+161,988	New	+$3.05M	0.59%	53
2025 Q2	–	Sell	-254,666	Closed	-$4.56M	–	325
2025 Q1	$4.56M	Buy	+254,666	New	+$5.17M	0.95%	23
2022 Q4	–	Sell	-57,605	Closed	-$1.42M	–	429
2022 Q3	$1.42M	Buy	57,605 +4,222	+8%	+$109K	0.23%	139
2022 Q2	$1.29M	Sell	53,383 -733	-1%	-$18.4K	0.21%	149
2022 Q1	$1.4M	Buy	54,116 +3,815	+8%	+$101K	0.17%	188
2021 Q4	$1.56M	Buy	+50,301	New	+$1.42M	0.18%	173

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Essex Investment Management's TVTX Position: Q1 2026 in Review

Essex Investment Management increased its Travere Therapeutics (TVTX) stake by 1.9% in Q1 2026, buying an estimated $89.6K and bringing the position to 161,705 shares worth $4.8M. The position accounts for 0.76% of the portfolio, ranked #39.

Essex Investment Management first reported a position in TVTX in Q4 2021 and has held it in 8 quarters since. The position peaked at $6.06M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Essex Investment Management held 161,705 shares of Travere Therapeutics worth $4.8M as of Q1 2026.
Essex Investment Management bought 2,996 Travere Therapeutics shares in Q1 2026, an estimated $89.6K.
Travere Therapeutics made up 0.76% of Essex Investment Management's portfolio in Q1 2026, its #39 holding.
Essex Investment Management first reported a position in Travere Therapeutics in Q4 2021 and has held it in 8 quarters since.
Essex Investment Management's Travere Therapeutics position peaked at $6.06M in Q4 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Essex Investment Management's 13F filing for Q1 2026, filed 11 May 2026.